GMT Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

GMT Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109M	Sell	453,500 -127,500	-22%	-$27.9M	5.69%	3
2026 Q1	$110M	Sell	581,000 -57,500	-9%	-$10M	5.01%	3
2025 Q4	$109M	Sell	638,500 -154,300	-19%	-$23.7M	5.66%	4
2025 Q3	$104M	Buy	792,800 +24,400	+3%	+$2.93M	4.74%	6
2025 Q2	$81.5M	Buy	768,400 +95,500	+14%	+$10.4M	3.41%	12
2025 Q1	$83.5M	Buy	672,900 +164,100	+32%	+$21.4M	4.43%	9
2024 Q4	$62.7M	Buy	508,800 +296,800	+140%	+$35M	3.05%	14
2024 Q3	$23.6M	Buy	+212,000	New	+$23.2M	0.94%	23

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

GMT Capital's JAZZ Position: Q2 2026 in Review

GMT Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 22% in Q2 2026, selling an estimated $27.9M and leaving 453,500 shares worth $109M. The position accounts for 5.69% of the portfolio, ranked #3.

GMT Capital first reported a position in JAZZ in Q3 2024 and has held it in 8 quarters since. The position peaked at $110M in Q1 2026. 645 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

GMT Capital held 453,500 shares of Jazz Pharmaceuticals worth $109M as of Q2 2026.
GMT Capital sold 127,500 Jazz Pharmaceuticals shares in Q2 2026, an estimated $27.9M.
Jazz Pharmaceuticals made up 5.69% of GMT Capital's portfolio in Q2 2026, its #3 holding.
GMT Capital first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
GMT Capital's Jazz Pharmaceuticals position peaked at $110M in Q1 2026.
645 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on GMT Capital's 13F filing for Q2 2026, filed 14 Aug 2026.